● Medix Biochemica 收購(gòu)了傳染病相關(guān)體外診斷用抗體、抗原領(lǐng)域的全球引領(lǐng)企業(yè)——美國(guó) ViroStat 公司。
Medix Biochemica has acquired the US-based ViroStat LLC, a global leader in infectious disease antibodies and antigens used by in vitro diagnostics (“IVD”) manufacturers.??
● 本次收購(gòu)極大補(bǔ)充了 Medix Biochemica 全球領(lǐng)先的體外診斷原料產(chǎn)品線、進(jìn)一步充實(shí)了科技實(shí)力，并加強(qiáng)了其在美國(guó)的力量。
The acquisition significantly expands Medix Biochemica’s leading portfolio of IVD raw materials, brings complementary scientific capabilities and further strengthens its local presence in the USA.?
● 本次交易有力推動(dòng)和加速 Medix Biochemica 成為全球 IVD 行業(yè)首選合作伙伴這一戰(zhàn)略愿景的實(shí)現(xiàn)，并加強(qiáng)其在傳染病檢測(cè)關(guān)鍵原料供應(yīng)的市場(chǎng)領(lǐng)導(dǎo)地位。
The transaction accelerates Medix Biochemica’s strategic vision of becoming the first-choice partner for the IVD industry worldwide and positions the organization as a market leader in the supply of critical raw materials to combat infectious diseases.?
—— 關(guān)于收購(gòu) ——
2023年11月10日，芬蘭埃斯波 – 體外診斷關(guān)鍵原料全球領(lǐng)先供應(yīng)商 Medix Biochemica 全資收購(gòu)了 ViroStat。通過(guò)此次并購(gòu)，Medix Biochemica 得以為其合作伙伴的試劑開(kāi)發(fā)提供行業(yè)領(lǐng)先的傳染病抗體、抗原。ViroStat 的運(yùn)營(yíng)將繼續(xù)保留在美國(guó)緬因州威斯布魯克進(jìn)行，其員工、包括總裁 Douglas McAllister 博士和總經(jīng)理 Duncan McAllister、在并購(gòu)后都將加入 Medix Biochemica。
10.11.2023, Espoo, Finland - Medix Biochemica, a global leader in the supply of critical raw materials to the in vitro diagnostics industry, has acquired 100 percent of the shares of ViroStat. As a result of the partnership, Medix Biochemica will be able to provide its customers with market-leading infectious disease antibodies and antigens for their IVD immunoassay test development. ViroStat operations will remain in Westbrook, Maine, and its employees – including President Dr. Douglas McAllister and General Manager Duncan McAllister – will join Medix Biochemica following the acquisition.
—— 關(guān)于ViroStat ——
ViroStat 由 Douglas McAllister 博士創(chuàng)立于 1985 年，是全球領(lǐng)先的高品質(zhì)抗體和抗原生產(chǎn)商，其產(chǎn)品主要用于呼吸道傳染病、性病、胃腸道疾病等病原體/毒素和食源性病原體的檢測(cè)。公司以其甲流、乙流、呼吸道合胞病毒和鏈球菌A等高親和力抗體在側(cè)向?qū)游鰬?yīng)用中的優(yōu)異表現(xiàn)而廣為人知。公司總部及生產(chǎn)設(shè)施均設(shè)于緬因州威斯布魯克。
Founded in 1985 by Dr. Douglas McAllister, ViroStat is a globally leading primary manufacturer of high-quality antibodies and antigens used for the detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens. For example, the company is widely known for its high affinity antibodies to Influenza A, Influenza B, RSV and Strep A for use in rapid lateral flow devices. ViroStat is headquartered and has its production site in Westbrook, Maine.
—— 共同愿景 ——
“我們熱烈歡迎 ViroStat 團(tuán)隊(duì)整體加入 Medix Biochemica”，Medix Biochemica 首席執(zhí)行官 Steve Ferguson 說(shuō)，“此次與 ViroStat 的合作為 Medix Biochemica 提供了市場(chǎng)領(lǐng)先的、全面的傳染病原料產(chǎn)品線，進(jìn)一步充實(shí)了科技實(shí)力，并強(qiáng)化了其在全球最大的體外診斷用抗原、抗體市場(chǎng)的網(wǎng)絡(luò)。ViroStat 和 Medix Biochemica 的合作有著悠久的歷史，我們高度認(rèn)可 Doug、Duncan、以及 ViroStat 全體成員在過(guò)去 38 年所建立的一切。我很高興雙方有著互補(bǔ)的產(chǎn)品線、相融的企業(yè)文化，期待我們一起發(fā)展、并為我們的全球客戶在與傳染病斗爭(zhēng)的過(guò)程中賦能。”
“We are very excited to welcome the whole ViroStat team to Medix Biochemica,” says Steve Ferguson, CEO of Medix Biochemica. “The partnership with ViroStat provides Medix Biochemica with market-leading products for broad range of infectious diseases as well as further strengthens our scientific capabilities and network in this largest diagnostic area of IVD antibodies and antigens. There has been a long-standing business relationship between ViroStat and Medix Biochemica, and we have great respect for what Doug, Duncan and the whole ViroStat team have built over the last 38 years. I am highly excited about the portfolio and cultural fit between our teams and looking forward to jointly growing our business to enable our customers to combat infectious diseases globally”.?
ViroStat 總裁 Douglas McAllister 博士說(shuō)：“與 Medix Biochemica 的合作意味著令人興奮的互補(bǔ)產(chǎn)品線及其帶來(lái)的協(xié)同效應(yīng)。我們緊密跟蹤傳染病的發(fā)展趨勢(shì)，及時(shí)針對(duì)新發(fā)傳染病開(kāi)展研發(fā)活動(dòng)，并在全球居家檢測(cè)需求即將快速增長(zhǎng)之際，為市場(chǎng)提供基于快速檢測(cè)平臺(tái)驗(yàn)證的抗體配對(duì)。我們很高興也很興奮能加入 Medix Biochemica 大家庭，這是天作之合。”
Douglas McAllister, President of ViroStat notes that “partnering with Medix Biochemica represents an exciting synergy of complementary product portfolios. ViroStat brings validated antibody pairs especially for rapid test IVDs at a time when worldwide demand for self-testing is poised for rapid growth while our R&D activity endeavors to stay ahead of new and emerging pathogens. We are very pleased and excited to be joining the Medix Biochemica family. This is a great fit.”
如需更多信息，請(qǐng)與聯(lián)系我們：
Medix Biochemica 中國(guó)商務(wù)團(tuán)隊(duì)
Commercial Team of Medix Biochemica China
電話: +86 21 6811 9180, 6811 9181, 6811 9105
郵箱: medixchina@medixbiochemica.com
網(wǎng)站: onb2b.cn
· 關(guān)于 Medix Biochemica
Medix Biochemica 集團(tuán)發(fā)起于芬蘭，服務(wù)于全球，是體外診斷行業(yè)領(lǐng)先的獨(dú)立關(guān)鍵原料供應(yīng)商。我們?yōu)槿蚝献骰锇殚_(kāi)發(fā)、生產(chǎn)、供應(yīng)高品質(zhì)抗體、抗原、以及其它體外診斷用關(guān)鍵原料，從而使全球億萬(wàn)患者得以獲得更精準(zhǔn)的體外診斷檢測(cè)結(jié)果。我們的技術(shù)專長(zhǎng)包羅萬(wàn)象，從免疫診斷原料，到分子診斷原料，以及生物樣本，還有定制服務(wù)。基于極為寬廣的IVD原料產(chǎn)品線，以及對(duì)業(yè)務(wù)深刻理解的團(tuán)隊(duì)，我們幫助合作伙伴縮短其產(chǎn)品上市所需時(shí)間，讓其產(chǎn)品質(zhì)量更為穩(wěn)定可靠。Medix Biochemica 擁有超過(guò) 300 名專業(yè)員工，通過(guò)在中國(guó)、美國(guó)、和歐洲的本地團(tuán)隊(duì)，我們服務(wù)于全球客戶。公司的主要股東是 DevCo 合伙公司，一個(gè)著眼長(zhǎng)遠(yuǎn)的所有者和發(fā)展伙伴，積極致力于在精選的細(xì)分市場(chǎng)建立并培育全球領(lǐng)先的公司。
· 關(guān)于 ViroStat
ViroStat 公司于 1985 年在美國(guó)成立，是傳染病相關(guān)抗體、抗原的首選生產(chǎn)商，為研究人員和體外診斷企業(yè)提供相關(guān)產(chǎn)品。公司以高品質(zhì)抗體知名，其產(chǎn)品的高批次一致性、穩(wěn)定可靠的供應(yīng)、一流的客戶服務(wù)和技術(shù)支持、以及長(zhǎng)期的伙伴關(guān)系得到了廣泛認(rèn)可。
